Thursday, May 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Talking innovations in healthcare delivery with Dr. Brittany Busse

We speak with Dr. Brittany Busse and learn about her new startup, ViTel Health

Dr. Brittany Busse has over five years of experience in Executive Physician Leadership and in developing processes and technology specific for Telemedicine. As a physician leader, Dr. Busse is a vocal advocate for the well-being of both providers and patients. She has been a featured expert and contributor for a variety of local, regional and national media publications.

Her curiosity for innovation and technology and her excitement for improving the healthcare system is contagious. As the president and CMO of ViTelHealth, she is dedicated to improving healthcare delivery and organizing digital health tools that augment the patient-provider connection and improve outcomes so that everyone can thrive. When she is not promoting change in healthcare, she enjoys practicing and teaching yoga and meditation, creating gourmet plant-based meals for herself and her partner, and hiking in Northern California with her rescue dog, Cabernet.

To learn more about ViTel Health, please select the following link: https://www.vitelhealth.com/

#chronic #CCM #RPM #primary #care #innovations #myvitelhealth

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!